GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » PensionAndRetirementBenefit

InnoCare Pharma (FRA:33C) PensionAndRetirementBenefit : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma PensionAndRetirementBenefit?

InnoCare Pharma's PensionAndRetirementBenefit for the quarter that ended in Dec. 2023 was €0.00 Mil.


InnoCare Pharma PensionAndRetirementBenefit Historical Data

The historical data trend for InnoCare Pharma's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma PensionAndRetirementBenefit Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
Get a 7-Day Free Trial - - - - -

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InnoCare Pharma PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


InnoCare Pharma (FRA:33C) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines